GlaxoSmithKline to Pay 37 States $41 Million Over Faulty Drugs
British drugmaker GlaxoSmithKline PLC has reached a $40.75 million settlement with 37 states for selling potentially faulty and contaminated medicines produced at its former Puerto Rico factory during the last decade, according to the Associated Press. The settlement divides the money among those states and the District of Columbia. They filed complaints against the company under their consumer protection laws following a $750 million criminal and civil settlement with the federal government last October. Both settlements involve production of adulterated, or substandard, products made from 2001 through 2004 at a factory in Cidra, Puerto Rico. Those included antidepressant Paxil CR plus anti-infection ointment Bactroban, sterile anti-nausea medication Kytril and combination Type 2 diabetes pill Avandamet. The federal criminal complaint alleged that the company did not ensure Kytril and Bactroban weren''t contaminated by microorganisms, that tablets may have contained too much or too little of the active ingredient, and that drugs of different types or strengths were mixed together in bottles. The case was brought after a company whistleblower reported on conditions in the factory to the Food and Drug Administration.